1. Introduction
===============

Both endogenous and exogenous cannabinoids can influence the course of infections *in vitro* and *in vivo*. This review will focus on viral infections of mammals, but will also describe what is known about other infections. Readers are directed to the excellent accompanying reviews in this issue which expertly discuss the clinical trials, cell biology, mechanisms of action, impact on inflammation, clinical applications, and so forth.

Cannabinoids may act either through the CB~1~ or the CB~2~ receptor, which are found on distinct cell types. The CB~1~ receptor is found on neurons as well as some astrocytes and skeletal muscle cells; neurons are frequently the target of viral infection. Engagement of the CB~1~ receptor by its endogenous or exogenous agonists may inhibit the release of Ca^2+^ from intracellular or extracellular stores. Since many important intracellular proteins are Ca^2+^-dependent for activation, signal transduction through the CB~1~ receptor may impair these secondary pathways and have a profound influence on the ability of viruses to replicate in neurons.

In contrast, the response of cells expressing the CB~2~ receptor may influence not only the responses in that cell, but may alter the course of the host innate and adaptive immune response to the pathogen, suppressing inflammation and the development of virus-specific cellular and humoral responses. The outcome on the viral infection will depend on whether inflammation is beneficial or pathogenic in the specific case.

2. Discussion
=============

When a host is infected with a virus, there is a dynamic competition between the ability of the host to first marshal innate (hours to days) and then adaptive immunity (\>7 days post infection) *vs.* the replication and spread of the virus first within the host and then to additional susceptible individuals. When a virus is able to out-pace the containment efforts, the host may succumb. Pathology may result from damage to tissues by viral-induced cellular apoptosis or necrosis, or alternatively, host immune responses may result in immunopathology or the perceived symptoms of the infection. If, however, innate and adaptive immunity successfully suppress viral replication, specific life-long immunity may result.

In order to understand the influences on the host response which may be the result of cannabinoids, it is important to examine some of the cellular pathways which are dependent on Ca^2+^-dependent enzymes. [Table 1](#pharmaceuticals-03-01873-t001){ref-type="table"} indicates some of the well characterized pathways involved and their potential impact on viral infections.

The common recurring impact of Ca^2+^-dependent enzymes is a role in inflammation. This ranges from regulation of many signal transduction pathways, production of pro-inflammatory and pro-resolving lipid mediators downstream of arachidonic acid, to activation of Nitric Oxide Synthase and the production of reactive nitrogen intermediates, to proteolytic enzymes which remodel the cytoskeleton or extracellular matrix, and apoptosis.

Inflammation is essential for recruitment of both innate and adaptive immune cells to the site of infection to control virus production and limit spread, and then to promote recovery. Inflammation is comprised not only of non-specific cells (sequentially these are polymorphonuclear leukocytes, natural killer cells, macrophages) and then pathogen-specific T lymphocytes recruited from circulation, and activation of antibody-secreting B lymphocytes, but also induction of production and secretion of cytokines, chemokines, interferons, complement components, acute phase reactants, reactive oxygen and nitrogen intermediates, and other mediators \[[@B24-pharmaceuticals-03-01873],[@B25-pharmaceuticals-03-01873],[@B26-pharmaceuticals-03-01873]\]. Readers are referred to the accompanying review by Bani, Mannaioni, Passani, and Masini \[[@B27-pharmaceuticals-03-01873]\]. Thus, many of these critical pathways may be impaired or compromised when endogenous or exogenous cannabinoids are present during an infection \[[@B28-pharmaceuticals-03-01873]\].

Cannabinoids have been used both recreationally by groups of people who have viral infections, and experimentally by scientists investigating their impact *in vitro* or in animal models. [Table 2](#pharmaceuticals-03-01873-t002){ref-type="table"} presents what has been published about these populations in peer reviewed journals. In most of the infections studied ([Table 2](#pharmaceuticals-03-01873-t002){ref-type="table"}), it is apparent that cannabinoid treatment, whether *in vitro* or *in vivo*, had profound impact on the virus-host (cell) interactions. For HSV-2, HIV-1, KSHV, influenza and VSV viral replication, or surrogate measures of infection, were found to be substantially increased upon cannabinoid treatment \[[@B30-pharmaceuticals-03-01873],[@B34-pharmaceuticals-03-01873],[@B39-pharmaceuticals-03-01873],[@B50-pharmaceuticals-03-01873],[@B52-pharmaceuticals-03-01873],[@B63-pharmaceuticals-03-01873]\]. In HIV-1 infection, syncytia formation was enhanced, and monocytes were stickier on endothelial cells \[[@B57-pharmaceuticals-03-01873],[@B58-pharmaceuticals-03-01873]\]. In one study, KHSV was more likely to exit latency and enter lytic infection when transformed cells were treated with THC \[[@B39-pharmaceuticals-03-01873]\], however, another study found the opposite result in several herpesvirus infections \[[@B38-pharmaceuticals-03-01873]\].

pharmaceuticals-03-01873-t001_Table 1

###### 

Some Ca^2+^-dependent enzymes which may be inhibited by Cannabinoids and speculated role in host responses relevant for viral infections.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Enzyme primary/secondary                       Pathways                                                                                                                         Ref.                                                                                                                                                                                               Role(s) in viral infection-host responses
  ---------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  cPhospholipase A~2~                            Arachidonic acid metabolites (prostaglandins, leukotrienes, lipoxins, resolvins) and inflammation                                \[[@B1-pharmaceuticals-03-01873],[@B2-pharmaceuticals-03-01873]\]                                                                                                                                  Inflammation and its resolution

  Phospholipase C\                               Production of Inositol 1,4,5-triphosphate from phosophotidylinositol                                                             \[[@B3-pharmaceuticals-03-01873]\]                                                                                                                                                                 Signal transduction
   - Receptor-mediated tyrosine kinase                                                                                                                                                                                                                                                                                                                                               

  Phospholipase D~1~                             Exocytosis in neuroendocrine cells                                                                                               \[[@B4-pharmaceuticals-03-01873]\]                                                                                                                                                                 Neurotransmission

  Calcineurin                                    Activation of NFAT---gene expression                                                                                             \[[@B5-pharmaceuticals-03-01873],[@B6-pharmaceuticals-03-01873]\]                                                                                                                                  Signal transduction

  Ca^2+^-Calmodulin\                             Conversion of argenine to NO in neurons and endothelial cells; production of ONOO-, -SNO, -R-NO~2~\                              \[[@B7-pharmaceuticals-03-01873],[@B8-pharmaceuticals-03-01873],[@B9-pharmaceuticals-03-01873],[@B10-pharmaceuticals-03-01873],[@B11-pharmaceuticals-03-01873],[@B12-pharmaceuticals-03-01873]\]   Anti-viral; NO~2~-decoration of viral proteins; capillary dilation; inflammation
   - Nitric oxide synthase-1\                    Inhibition of viral infection                                                                                                                                                                                                                                                                                                       
   - Nitric oxide synthase-3                                                                                                                                                                                                                                                                                                                                                         

  Ca^2+^-Calmodulin dependent protein kinases\   Wnt-2-dependent dendrite growth & cardiomyogenesis\                                                                              \[[@B13-pharmaceuticals-03-01873],[@B14-pharmaceuticals-03-01873],[@B15-pharmaceuticals-03-01873],[@B16-pharmaceuticals-03-01873],[@B17-pharmaceuticals-03-01873]\]                                Adaptive immune responses; inflammation
      - CREB\                                    \                                                                                                                                                                                                                                                                                                                                   
      - CaMKK activation of AMPK                 Energy, epithelial cell polarity\                                                                                                                                                                                                                                                                                                   
                                                 \                                                                                                                                                                                                                                                                                                                                   
                                                 T cell activation                                                                                                                                                                                                                                                                                                                   

  Calpains \[Ca^2+^-dependent proteases\]        Neutral proteases \[many tissues\]\                                                                                              \[[@B18-pharmaceuticals-03-01873],[@B19-pharmaceuticals-03-01873],[@B20-pharmaceuticals-03-01873]\]                                                                                                Cytoskeletal plasticity, cell migration, inflammation
                                                 Cell membrane fusion, synaptic remodeling, activating PKC, remodeling cytoskeleton, transcription factors                                                                                                                                                                                                                           

  Matrix metalloproteinases                      Extracellular matrix remodeling, inflammation                                                                                    \[[@B21-pharmaceuticals-03-01873]\]                                                                                                                                                                Inflammation

  Calpastatin                                    Cell fusion in fertilization                                                                                                     \[[@B22-pharmaceuticals-03-01873]\]                                                                                                                                                                Formation of heterokaryons /giant cells

  Transglutaminases                              Cross-linking/deamination of proteins --wound healing, tissue repair, apoptosis, cell cycle control, inflammation and fibrosis   \[[@B23-pharmaceuticals-03-01873]\]                                                                                                                                                                Inflammation, fibrosis, cell cycle and programmed cell death
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

pharmaceuticals-03-01873-t002_Table 2

###### 

Cannabinoids and Viral Infections.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Viral pathogen                  *In vivo In vitro*   Agonist / Antagonist            Titer change                                      Pathogenesis                                                                   Inflammation Immunoregu-lation                                                    Comments                                                                                       Ref.
  ------------------------------- -------------------- ------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  HSV-2,\                         *In vivo*            Δ9-THC                                                                            decreased resistance to LD~50~                                                                                                                                   systemic infection                                                                             \[[@B29-pharmaceuticals-03-01873]\]
  *L. monocyto-genes*                                                                                                                                                                                                                                                                                                                                                                                    

  HSV-2                           *In vivo*            Δ9-THC                          increased shedding                                increased severity of lesions & mortality                                      delayed onset of DTH response                                                     vaginal model B6C3H F~1~ mouse                                                                 \[[@B30-pharmaceuticals-03-01873]\]

  HSV-2                           *In vivo*            Δ9-THC                                                                                                                                                           decreased Type I IFN response                                                     i.v. infection                                                                                 \[[@B31-pharmaceuticals-03-01873]\]

  HSV-2                           *In vivo*            Δ9-THC                                                                            decreased resistance to infection; increased severity of lesions                                                                                                 vaginal guinea pig model                                                                       \[[@B32-pharmaceuticals-03-01873]\]

  HSV-1,-2                        *In vitro*           Δ9-THC                          failed to replicate                                                                                                                                                                                                antiviral effect in human & monkey cells                                                       \[[@B33-pharmaceuticals-03-01873]\]

  HSV-2                           *In vitro*           Δ9-THC                          100-fold increase in released virus                                                                                                                                                                                Vero cells, increased CPE                                                                      \[[@B34-pharmaceuticals-03-01873]\]

  HSV-2                           both                 Δ9-THC                                                                                                                                                           decreased T cell proliferation                                                    B6C3H F~1~ mice immunized then T cells cultured                                                \[[@B35-pharmaceuticals-03-01873]\]

  HSV                             *In vitro*           Δ9-THC                          decreased infectivity in TC                                                                                                                                                                                        virus incubated with THC                                                                       \[[@B36-pharmaceuticals-03-01873]\]

  HSV-1                           both                 Δ9-THC                                                                                                                                                           decreased CD8 CTL activity                                                        C3H mice immunized, L929 targets                                                               \[[@B37-pharmaceuticals-03-01873]\]

  EBV, KSHV, HVS, HSV-1, MHV-68   *In vivo*            Δ9-THC                          Immediate early ORF promoter activity inhibited   reactivation from latency inhibited                                                                                                                              latently infected B cells in tissue culture                                                    \[[@B38-pharmaceuticals-03-01873]\]

  KSHV                            *In vivo*            Δ9-THC                          increased viral load                              increased efficiency of infection, activation of lytic switch                  increased transformation of endothelial cells                                     primary human dermal microvascular cells                                                       \[[@B39-pharmaceuticals-03-01873]\]

  Cowpox                          *In vivo*            Marijuana cigarettes                                                              generalized infection                                                          weak Ab production, no neutralizing Abs                                           Case report                                                                                    \[[@B40-pharmaceuticals-03-01873]\]

  TMEV                            *In vitro*           Anandamide                                                                                                                                                       decreased release of NO2- and TNF-α                                               NO is antiviral for TMEV                                                                       \[[@B41-pharmaceuticals-03-01873],[@B42-pharmaceuticals-03-01873]\]

  TMEV                            *In vitro*           Anandamide                                                                                                                                                       increased IL-6 production                                                         astrocyte culture B6 and SJL mice                                                              \[[@B43-pharmaceuticals-03-01873]\]

  TMEV                            *In vivo*            WIN-55,212                                                                        ameliorates progression of autoimmune disease TMEV-IDD                         decreased DTH, decreased IL-1, IL-6, IFN-γ , TNF-α,                               TMEV-IDD a mouse model of MS                                                                   \[[@B44-pharmaceuticals-03-01873]\]

  TMEV                            *In vivo*            OMDM1, OMDM2                                                                      ameliorated motor symptoms                                                     decreased MHC II, inhibited NOS-2, reduced proinflammatory cytokines              TMEV-IDD proposed MS therapy with cannabinoids                                                 \[[@B45-pharmaceuticals-03-01873]\]

  TMEV                            *In vitro*           JWH-133 SR144558                                                                  role of CB~2~ receptors in anti-inflammatory actions                           reduced IL-12p40, reduced ERK1/2 signaling                                                                                                                                       \[[@B46-pharmaceuticals-03-01873]\]

  TMEV                            *In vitro*           WIN-55,212                                                                        CB~2~-dependent COX-2 induction increased vs. TMEV-alone                       role of PI3 kinase pathway in CB~2~ but MAPK for TMEV signaling                   proposed role on blood-flow and immune activity                                                \[[@B47-pharmaceuticals-03-01873]\]

  TMEV                            *In vivo*            Palmitoyl-ethanol-amine                                                           reduction in motor disability in TMEV-IDD                                      anti-inflammatory effect                                                          TMEV-IDD                                                                                       \[[@B48-pharmaceuticals-03-01873]\]

  TMEV                            both                 WIN-55,212                                                                        inhibited ICAM & VCAM on endothelium; role for PPAR-γ receptors in mechanism   reduced inflammation                                                              TMEV-IDD                                                                                       \[[@B49-pharmaceuticals-03-01873]\]

  Influenza                       *In vivo*            Δ9-THC                          HA mRNA increased                                 inflammation, metaplasia of mucous cell                                        decreased CD4, CD8, and macrophage recruitment                                                                                                                                   \[[@B50-pharmaceuticals-03-01873]\]

  Influenza                       *In vivo*            Δ9-THC                          HA mRNA decreased in CB~1~/CB~2~KO mice           THC-mediated airway pathology +/- CB~1~/CB~2~                                  KO mice had increased CD4 and IFN-γ recruitment                                   CB~1~/CB~2~KO mice                                                                             \[[@B51-pharmaceuticals-03-01873]\]

  VSV                             *In vitro*           WIN-55,212                      increased viral titers                            CB~1~-dependent; decreased NOS-1 activity                                      antagonized IFN-γ-mediated antiviral pathway                                      suggested disease progression likely in neurons/viral encephalitis                             \[[@B52-pharmaceuticals-03-01873]\]

  BDV                             *In vivo*            WIN-55,212                                                                        protected BrdU-positive neural progenitor cells in striatum                    suppressed microglial activation                                                  suggested treatment of encephalitis with microglial inflammation and neuro-degeneration        \[[@B53-pharmaceuticals-03-01873]\]

  HCV                             *In vivo*            Marijuana cigarettes                                                              progression of liver fibrosis                                                                                                                                    epidemiological study                                                                          \[[@B54-pharmaceuticals-03-01873]\]

  HCV                             *In vivo*            Oral cannabinoids                                                                 improved weight                                                                no viral markers or immune markers studied                                        7 week clinical trial for anorexia and nausea                                                  \[[@B55-pharmaceuticals-03-01873]\]

  HCV                             *In vivo*            Marijuana cigarettes                                                              progression of liver fibrosis; increased disease severity                                                                                                        clinical pathological survey of 204 HCV patients                                               \[[@B56-pharmaceuticals-03-01873]\]

  HIV-1                           *In vitro*           Δ9-THC, CP-55,940, WIN-55,212                                                     increased syn-cytia formation MT-2 cells (CB~1~ & CB~2~^+^)                                                                                                      speculate cannabinoids enhance HIV-1 infection                                                 \[[@B57-pharmaceuticals-03-01873]\]

  HIV-1                           *In vitro*           anandamide                                                                        increased adherence for monocytes                                              uncoupled NO release, inhibited NO                                                human saphenous vein or internal thoracic artery; speculate higher titers *in vivo*            \[[@B58-pharmaceuticals-03-01873]\]

  HIV-1 Tat                       *In vitro*           WIN-55,212                                                                        reduced tat-induced cytotoxicity                                               inhibited NOS-2 activity                                                          C6 rat glioma cell line                                                                        \[[@B59-pharmaceuticals-03-01873]\]

  HIV-1                           *In vivo*            Marijuana cigarettes                                                              increased appetite                                                             insufficient numbers of individuals                                               3 week trial                                                                                   \[[@B60-pharmaceuticals-03-01873]\]

  HIV-1                           *In vivo*            Marijuana cigarettes            mRNA unchanged                                                                                                                   CD4+ and CD8+ cells unchanged                                                     3 week trial, placebo-controlled                                                               \[[@B61-pharmaceuticals-03-01873]\]

  HIV-1                                                WIN-55,212                      inhibited expression                                                                                                                                                                                               CD4 and microglial cultures                                                                    \[[@B62-pharmaceuticals-03-01873]\]

  HIV-1                           *In vivo*            THC                             increased viral replica-tion 50-fold                                                                                             decreased CD4 IFN-γ-producing cells, increased co-receptor expression             scid-Hu mouse model                                                                            \[[@B63-pharmaceuticals-03-01873]\]

  HIV-1 Gp120                     *In vitro*           2-AG, CP55940                                                                     inhibited Ca^+2^-flux-induced substance P, decreased permeability                                                                                                model of BBB, co-culture of Human brain microvascular endothelial cells and astrocytes         \[[@B64-pharmaceuticals-03-01873]\]

  HIV-1                           *In vivo*            WIN-55,212                                                                        dose-related hypothermia in mouse pre-optic anterior hypothalamus infusion     WIN-55,212 is antagonist for SDF-1a/ CXCL12/ CXCR4 \[HIV-1 coReceptor\] pathway   mouse model for HIV-thermoreg-ulation by direct injection of WIN-55,212 to brain POAH center   \[[@B65-pharmaceuticals-03-01873]\]

  HIV-1 Tat                       *In vitro*           CP55940, Δ9-THC                                                                   CB~2~-dependent inhibition of U937 migration to Tat                            possible anti-inflammatory mechanism                                              U937 cells in culture                                                                          \[[@B66-pharmaceuticals-03-01873]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Legend: BDV, Borna disease virus; EBV, Epstein-Barr virus; HCV, Hepatitis C virus; HIV, Human immunodeficiency virus; HSV, Herpes simplex virus; HVS, Herpes virus samirii; KO, knock-out mice; KSHV, Kaposi\'s sarcoma herpes virus; *L. monocytogenes, Listeria monocytogenes*; MHV-68, Murine herpes virus-68; TMEV, Theiler\'s murine encephalomyelitis virus; VSV, Vesicular stomatitis virus.

Disease was more severe in HSV-2-infected guinea pigs which were treated with THC \[[@B29-pharmaceuticals-03-01873],[@B30-pharmaceuticals-03-01873],[@B32-pharmaceuticals-03-01873]\]. In HCV infections, clinical studies have shown a profound co-morbidity of recreational cannabinoid use, for disease progression \[[@B54-pharmaceuticals-03-01873],[@B56-pharmaceuticals-03-01873]\]. One case report of Cowpox infection, a very rare human pathogen, indicated that recreational use of cannabinoids was associated with generalized infection and very poor immune responses to the virus \[[@B40-pharmaceuticals-03-01873]\].

In contrast, in those infections where host inflammatory responses are often associated with pathology, and not with clearance and recovery, cannabinoid treatment of hosts was beneficial. These included one mouse model of multiple sclerosis, the Theiler\'s murine encephalomyelocarditis virus (TMEV)-induced demyelinating disease (IDD), where progression towards the paralysis and disability were ameliorated \[[@B44-pharmaceuticals-03-01873],[@B45-pharmaceuticals-03-01873],[@B48-pharmaceuticals-03-01873]\] and in Borna disease virus (BDV) where neural progenitors were protected from proinflammatory cytokine-mediated damage \[[@B53-pharmaceuticals-03-01873]\] infections. TMEV-IDD is characterized by microglial activation in the spinal cord of mice and a T cell-mediated autoimmune demyelinating disease, triggered by the viral infection \[[@B42-pharmaceuticals-03-01873],[@B67-pharmaceuticals-03-01873],[@B68-pharmaceuticals-03-01873],[@B69-pharmaceuticals-03-01873]\]. Persistent BDV infection of the central nervous system is associated with immunopathology associate with inflammation and production of pro-inflammatory cytokines, induction of NOS-2 in microglia, and breakdown of the blood-brain barrier \[[@B70-pharmaceuticals-03-01873],[@B71-pharmaceuticals-03-01873],[@B72-pharmaceuticals-03-01873],[@B73-pharmaceuticals-03-01873]\]. In both BVD and TMEV-IDD, the targets for the anti-inflammatory effects of the cannabinoid treatment are lymphocytes and mononuclear cells.

Two excellent reviews of the impact of cannabinoids on bacterial, yeast, and protozoan infections were published in the same issue of *Journal of Neuroimmunology* \[[@B26-pharmaceuticals-03-01873],[@B74-pharmaceuticals-03-01873]\]. These infections included *Treponema pallidum* (Syphilis), *Legonella pneumophila* (Legionnaires\' disease), *Staphylococci aureus* and*S. albus*, *Listeria monocytogenes, Candida albicans* (Thrush), and *Naegleria fowleri*. Both reviews concluded that THC significantly reduced host resistance to infection of experimental animals, and speculated that similar host compromise would be found in man. In the more than 12 years since those reviews were published, additional findings have extended the serious consequences of cannabinoids on host responses to pathogens and opportunistic infections. Marijuana use is a risk factor for *Mycobacterium tuberculosis* (TB) infections \[[@B75-pharmaceuticals-03-01873],[@B76-pharmaceuticals-03-01873],[@B77-pharmaceuticals-03-01873]\]; this author speculates the suppression of host innate immune responses by THC contributes to the increased severity of TB in users. Similarly, more serious exacerbations central nervous system infection by *Acanthamoeba* among HIV-infected patients has been attributed to marijuana consumption \[[@B78-pharmaceuticals-03-01873]\], possibly by inhibiting macrophage chemotaxis \[[@B79-pharmaceuticals-03-01873]\]. However, the antiinflammatory effects of cannabinoids have been found to be beneficial in attenuating fever induced by bacterial endotoxin \[[@B65-pharmaceuticals-03-01873],[@B80-pharmaceuticals-03-01873]\], inhibiting cytokine responses to *Corynebacterium parvum* endotoxin \[[@B81-pharmaceuticals-03-01873]\]. These drugs may also offer therapeutic efficacy in meningitis caused by *Streptococcus pneumoniae* \[[@B82-pharmaceuticals-03-01873]\] and in irritable bowel syndrome \[[@B83-pharmaceuticals-03-01873],[@B84-pharmaceuticals-03-01873]\].

Cannabinoids may relieve pain and may induce hyperphagia, which could be beneficial in cancer \[[@B85-pharmaceuticals-03-01873],[@B86-pharmaceuticals-03-01873]\]. However, these physiological characteristics are not relevant to most viral, bacterial fungal or parasitic infections, where the regulation of inflammation is central to controlling pathogen replication and immunopathology. However, the same anti-inflammatory properties of cannabinoids just described are detrimental to the host in handling the other infections. In most cases, a rapid and robust inflammatory response, associated with production of proinflammatory cytokines and effect T lymphocytes capable of eliminating infected cells is essential to recovery and survival.

3. Conclusions
==============

Cannabinoids are profoundly anti-inflammatory and impair many Ca^2+^-dependent enzyme systems which are central to inflammatory and cell-autonomous antiviral responses. When viral-induced host responses lead to immunopathology, as is seen in a rodent model of multiple sclerosis, TMEV-IDD, or in a persistent infection of the central nervous system caused by a non-lytic virus, BDV, cannabinoid treatment was beneficial.

In all other virus infections, both *in vitro* and *in vivo*, cannabinoid treatment led to disease progression, increased pathology, and sometimes to host death. Therefore, in many clinical settings, including latent infections caused by HIV-1 or HSV-1, and persistent infection of the liver caused by HCV, cannabinoids lead to worsened disease outcome.
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